Tonsillitis causes considerable short and medium term morbidity, and can be recurrent.
Sinusitis can be acute (less than 4 weeks), subacute (4-8 weeks) or chronic (8 weeks or more). To study the comparative efficacy and safety of multidose treatments of
lincomycin hydrochloride 500 mg capsules against
cefpodoxime proxetil 200 mg
tablets on its outcome in the Indian scenario are the aims and objective of the study. A total of 41
tonsillitis,
sinusitis cases of either gender aged above 18 years were enrolled in the study. The diagnosis of sonsillitis,
sinusitis was made based on examination of symptoms and throat swab. A randomised treatment of either
lincomycin hydrochloride 500 mg capsules or
cefpodoxime proxetil 200 mg
tablets twice daily for five days alongwith other concomitant medications depending on related symptoms was given to 40 patients. At the end of study, all patients were re-evaluated and the response rate was assessed. The most common clinical symptoms were body temperature,
headache, throat
pain, postnasal discharge, mucopus, odynophagia, sinus tenderness, nasal congestion, pharyngeal congestion and tonsillar congestion. The overall response rate of
lincomycin hydrochloride in all the symptoms except
headache was more effective than
cefpodoxime proxetil. Out of 100% (n = 20) patients in each group, 67.89% in
lincomycin and 52.27% in
cefpodoxime patients achieved complete relief, in all the clinical symptoms. The study suggests that
lincomycin hydrochloride capsules, a conventional
antibiotic indicates effective treatment for relief from
tonsillitis and
sinusitis, as compared to new third generation
antibiotic.